Workflow
鹰瞳科技(02251) - 2022 - 年度业绩
AIRDOCAIRDOC(HK:02251)2023-03-23 14:58

Financial Performance - The total comprehensive income for the year ended December 31, 2022, was RMB (182.7) million, compared to RMB (142.5) million in 2021[11]. - Revenue for the year ended December 31, 2022, was RMB 113,657,000, a decrease of 1.4% from RMB 115,181,000 in 2021[25]. - Gross profit for 2022 was RMB 55,852,000, down 20.5% from RMB 70,241,000 in 2021[25]. - Operating loss for 2022 was RMB 182,301,000, compared to an operating loss of RMB 142,229,000 in 2021[25]. - The company reported a net loss of RMB 182,740,000 for 2022, compared to a net loss of RMB 142,527,000 in 2021[25]. - The company recorded a loss of RMB 182.7 million for the year ending December 31, 2022, compared to a loss of RMB 142.5 million in 2021[93]. - The company reported a net loss attributable to equity shareholders of RMB 180,003,000 for 2022, compared to RMB 142,634,000 in 2021[189]. - Revenue decreased by 1.3% from RMB 115.2 million in 2021 to RMB 113.7 million in 2022, primarily due to reduced income from the Eagle Health business[84]. Assets and Liabilities - As of December 31, 2022, the company's non-current assets included property, plant, and equipment valued at RMB 33.1 million, down from RMB 44.9 million in 2021[12]. - The total non-current assets increased to RMB 64,137,000 in 2022 from RMB 48,566,000 in 2021[25]. - Cash and cash equivalents decreased from RMB 1,784.6 million in 2021 to RMB 1,268.3 million in 2022, primarily due to cash expenditures for financial asset purchases and operational activities[98]. - The company's inventory increased from RMB 7.7 million in 2021 to RMB 29.6 million in 2022, mainly due to procurement and reserve of raw materials for the self-developed fundus camera[96]. - Accounts receivable increased from RMB 34.0 million as of December 31, 2021, to RMB 63.9 million as of December 31, 2022, with average turnover days rising from 87 days to 169 days[125]. - Contract liabilities grew from RMB 17.1 million as of December 31, 2021, to RMB 18.2 million as of December 31, 2022, primarily due to increased customer prepayments[129]. - Current liabilities as of December 31, 2022, were RMB 64.7 million, with accounts payable decreasing to RMB 42.0 million[152]. - The net assets as of December 31, 2022, were RMB 1,671,362,000, a decrease from RMB 1,819,986,000 in 2021[176]. Research and Development - R&D expenses rose by 95.4% from RMB 64.3 million in 2021 to RMB 125.6 million in 2022, driven by an expanded R&D team and ongoing investments in AI software solutions[89]. - Research and development expenses increased significantly to RMB 125,594,000 in 2022, up from RMB 64,265,000 in 2021, reflecting a focus on innovation[189]. - The R&D team consists of 114 members, all with at least a bachelor's degree, which is a cornerstone of the company's success[101]. - The company has developed over 90 deep learning algorithms to cover a wide range of diseases, lesions, and health risks, enhancing its existing pipeline for chronic disease early detection and diagnosis[67]. - The company is focused on integrating software, algorithms, hardware, and services into a comprehensive solution, enhancing user experience and optimizing algorithms for better screening efficiency and diagnostic accuracy[68]. Product Development and Commercialization - The company has developed a comprehensive AI-based solution for early detection and diagnosis of various diseases, including 55 conditions in its health risk assessment solutions[29]. - The AI-FUNDUSCAMERA-D received regulatory approval in July 2022 and is set for commercialization in various healthcare settings[37]. - The company completed clinical trials for Airdoc-AIFUNDUS (2.0) in Q3 2022 and applied for a new indication for the Class III medical device registration in Q4 2022[52]. - Airdoc's new myopia treatment device utilizes its AI algorithms for real-time tracking and aims to control myopia progression through low-intensity light exposure[64]. - The company plans to submit registration applications for AI-FUNDUSCAMERA-M and myopia treatment devices in the fourth quarter of 2023[29]. Market and Customer Growth - The number of customers increased from 244 in 2021 to 397 in 2022, representing a growth of approximately 62.3%[47]. - The average charge per test rose to RMB 20.3, a 4.5% increase from RMB 19.9 in 2021, attributed to improved AI solution capabilities[47]. - Revenue from Airdoc-AIFUNDUS (1.0) sales reached RMB 25.1 million, while total revenue from Eagle Eye Medical amounted to RMB 28.2 million[49]. - The company’s AI solutions were implemented in over 180 health check centers and more than 1,200 optical centers across China in 2022[52]. - Over 780 pharmacies utilized the health risk assessment solutions, with the average number of service points increasing by over 200% year-on-year[50]. Expenses and Financial Management - Sales cost increased by 28.6% from RMB 44.9 million in 2021 to RMB 57.8 million in 2022, mainly due to increased procurement costs for myopia treatment devices[85]. - Sales expenses rose by 37.8% from RMB 72.6 million in 2021 to RMB 100.0 million in 2022, driven by the expansion of the sales and marketing team[119]. - Administrative expenses for the year ended December 31, 2022, were RMB 80.1 million, compared to RMB 77.1 million in 2021[120]. - Other income increased from RMB 1.4 million in 2021 to RMB 67.5 million in 2022, primarily due to foreign exchange gains of RMB 58.6 million[116]. Strategic Initiatives - The company has proposed a 2022 equity incentive plan, pending approval at the special general meeting on March 30, 2023[5]. - The company is strategically seeking investment and acquisition opportunities to drive long-term growth[136]. - The company plans to optimize and commercialize core products, with a budget allocation of RMB 775.4 million, representing 50% of total net proceeds[140]. - Research and development for health risk assessment solutions is budgeted at RMB 155.1 million, accounting for 10% of total net proceeds[140]. Regulatory and Compliance - The company has submitted an application for full circulation of H shares to the China Securities Regulatory Commission[7]. - The company has adopted several amendments to the International Financial Reporting Standards, which did not have a significant impact on its financial statements[195]. - The company has not applied any new amendments that are not yet effective in the current accounting period[195].